Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:
”Primary immune thrombocytopenia (ITP) is a rare autoimmune blood disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue. For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects.
Today, we announced positive top-line results from our investigational treatment in primary ITP.
This marks our second positive data readout for this investigational asset as yesterday we announced positive Phase III results in Sjögren’s disease – reinforcing our efforts to addressing areas of high unmet needs across B-cell driven diseases.
With over two decades of experience advancing care in ITP, this milestone underscores our commitment to continuing to innovate with the aim of finding new and meaningful ways to improve patient outcomes.
I would like to extend my gratitude to the patients, families, and teams who made this possible as we reimagine medicine together.”
Read more about Shreeram Aradhye’s announcement here.
Stay updated on the latest breakthroughs in drug development with Hemostasis Today.
-
Sep 30, 2025, 11:43Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
-
Sep 30, 2025, 06:43Sara García Barcenilla: What Better Way to Celebrate ''World ITP Day'' Then With The Interview of Nora Butta and Daniel Aníbal García-Diego
-
Sep 30, 2025, 06:42Courtney Battaglia: AFib Can Cause Racing Heartbeat or Fatigue and Also Raises The Risk of Stroke!
-
Sep 29, 2025, 22:44Pall T. Onundarson on Correlation Between Plasma Levels of DOACs and Both Thromboembolic and Bleeding Events
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 30, 2025, 06:45Robert Mikulik and Colleagues Show Differences in Acute Ischemic Stroke Treatment
-
Sep 30, 2025, 06:40Cihan Ay: Can AI Match Thrombosis Experts?
-
Sep 29, 2025, 19:56Luisa Hora de Carvalho and Colleagues Highlight The Challenges in Evaluating Thromboembolic Risk in Acute Leukemia
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 11:48Nan van Geloven on Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 19:39Louise Bannon: Today is World Heart Day, And It's Deeply Personal For Me
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe